Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration

International Journal of Antimicrobial Agents

Volumn 48, Issue 3, 2016, Pages 342-343

  Kuti, Joseph L ^a   Ghazi, Islam M ^a   Quintiliani, Richard ^a   Shore, Eric ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTOLOZANE PLUS TAZOBACTAM; HYPERTENSIVE FACTOR; LEVOFLOXACIN; MEROPENEM; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; URINARY TRACT ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; AGED; ANTIBIOTIC THERAPY; BACTERIAL GROWTH; CLINICAL FEATURE; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; HYPOXIA; LETTER; LEUKOCYTE COUNT; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; TRACHEAL ASPIRATION PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA; VERY ELDERLY; ANALOGS AND DERIVATIVES; CASE REPORT; CHEMISTRY; CRITICAL ILLNESS; DRUG EFFECTS; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PLASMA; PSEUDOMONAS INFECTIONS; UNITED STATES;

AGED; ANTI-INFECTIVE AGENTS, URINARY; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEMOFILTRATION; HUMANS; MALE; PENICILLANIC ACID; PLASMA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 84978865098     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.06.005     Document Type: Letter

References (5)

1. [1] Sutherland, C.A., Nicolau, D.P., Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Ther 37 (2015), 1564–1571.
2. [2] Gelfand, M.S., Cleveland, K.O., Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis 61 (2015), 853–855.
3. [3] Bremmer, D.N., Nicolau, D.P., Burcham, P., Chunduri, A., Shidham, G., Bauer, K.A., Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy 36 (2016), e30–3.
4. [4] Oliver, W.D., Heil, E.L., Gonzales, J.P., Mehrota, S., Robinett, K., Saleeb, P., et al. Ceftolozane–tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother 60 (2016), 1899–1901.
5. [5] Patel, U.C., Nicolau, D.P., Sabzwari, R.K., Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane/tazobactam regimen. Infect Dis Ther 5 (2016), 73–79.